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Immunoglobulin (Ig) allotype suppressionwasfirstdescribed in heterozygous rabbits
by Dray(1), who showed in 1962 that perinatalexposureto antibodiesdirected against
paternally inherited Ig allotypes (2-5) would suppress their expression. One ofthe
interesting developments inthe fieldmadepossibleby this pioneerworkwere successful
attempts to induce allotype suppression inhomozygous rabbits. However, for this pur-
pose, newmethods had tobeused, becauselargeamounts ofmaternal Ig passthrough
the placenta and are present in the fetus, thereby blocking the effects ofeventual
anti-allotypicantibody treatment commonly used to induce suppression. Thisproblem
was originally circumvented in 1967 by Dubiski (6), who mated a heterozygous fe-
male rabbit subjected to suppressionfor a paternal allotype with amale rabbit homozy-
gous for this allotype. Other methods were then elaborated, such as homozygous
embryo transferto surrogatemothers ofappropriate genotype (7, 8). The obtention
ofallotype-suppressed homozygous rabbits allowed inparticular thediscoveryofnew
Ig allotypic specificities and some insights in the regulation of Ig expression (9).
For instance, thecompensatory effect (1) observed in allotype-suppressed rabbitswas
dueto an increased expression either ofallelic genes when consideringheterozygous
rabbits (1) or of genes at different loci in the case ofhomozygous rabbits (6).
Studies in mice on the effect ofisoantibodies on paternal Ig allotype started soon
afterDray's discovery ofrabbit allotypic suppression (10). Theywere mainly achieved
in (BALB/c x C57BL/6)Fi mice and allowed the obtention ofshort term allotypic
suppression (11). Then, chronic allotypic suppression was induced (12) in BALB/c
(Igha) x SJL (Ighb)Ft mice, where the BALB/c mothers were immune to IgG2a
of Ighb haplotype (Igh-lb). At 6 mo of age, a chronic Igh-lb suppression was ob-
served in 50% of the offsprings. It should be noted that antibody-induced Igh-lb
chronic suppression occurred only in SJL-related hybrids. This suppression exhibited
several differences with the phenomenon described in rabbits, but it provided a powerful
approach in understanding its cellular bases (reviewed in reference 13).
We have recently succeeded in inducing chronic allotype suppression of Igh-lb
expression in Igha'b hybrid mice issued from matings between Igh congenic partners
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that were not SJL-related. This was achieved by injecting the heterozygous mice
at birth with T splenocytes either from Igha normal parental donors (14) or, with
a much higher efficiency, from Igha parental donors sensitized against either Igh-
Ib-coated autologous splenocytes or Ighb congenic B splenocytes (15). This sensiti-
zation procedure was particularly powerful, as it allowed the induction ofthis Igh-lb
suppression in Ighbla mice having maternally inherited the Ighb haplotype (15).
This, together with the fact that anti-allotypic antibodies were shown to be absent
from this induction procedure (15), led us to attempt to induce Igh-lb suppression
in homozygous mice without resorting either to embryo transfer, as in experiments
with rabbits, or to irradiation of adult recipients, as in the mouse experimental model
of Bosma and Bosma (16). Homozygous mice (Ighb1b) received at birth a single in-
jection of T splenocytes from Igha congenic mice sensitized against parental Ighb
B splenocytes. We report here that in two different systems of Igh congenic mice,
all the treated animals developed a chronic suppression ofthe Igh-Ib expression without
affecting the expression of IgM, IgD, and IgA of the Ighb haplotype. Further, we
show that the suppression can be experimentally abrogated and that CD8' lym-
phocytes are essential for its maintenance.
Materials and Methods
Mice.
￿
9-13-wk-old female or male BALB/c, CB20, C57BL/6, and BC8 mice were from
our animal facilities. CB20 is a BALB/c congenic strain having the Igh genes (Ighb) of the
C57BL/6 strain, while BC8 is a C57BL/6 congenic strain having the Igh genes (Igha) of the
BALB/c strain. To designate the F, mice, we used the usual convention, namely, the mother's
name indicated first, followed by the father's name.
Cell Preparation.
￿
Splenocytes were separated on nylon wool columns as previously described
(17). Using a rat anti-mouse Thy-1.2 mAb (a gift of Dr. Coutinho, Institut Pasteur, Paris)
followed by goat anti-rat antibodies adsorbed on mouse Ig (Cappel Laboratories, Cochran-
ville, PA) and labeled with FITC, we found 7517o positive cells within the nylon wool-nonad-
herent splenocyte population (Tj),' while the use of FITC-labeled Fab fragments of goat
anti-mouse Ig (Nordic Immunological Laboratories, Tilburg, The Netherlands) revealed,
in the same population, <5% positive cells. To prepare large amounts of B-enriched spleno-
cytes, total splenocyte populations were incubated with the rat antiThy-1.2 mAb plus guinea
pig complement. To prepare peripheral blood lymphocytes, til ml of blood per mouse was
collected on heparin by retro-orbital sinus puncture. This blood was diluted with 1 ml of
balanced salt solution and carefully layered on 2 ml of Lympholyte M (Cedarlane Laborato-
ries, Hornby, Ontario, Canada). After centrifugation at room temperature for 17 min at 420
g, white cells were harvested at the interface and washed twice before use.
Mouse Sensitizations andNewborn Treatments.
￿
Treatments were carried out as previously de-
scribed (15). For sensitizations, female BALB/c or BC8 mice were injected, by the intrave-
nous route, with 0.1-0.2 ml of balanced salt solution containing 5 x 10' B-enriched spleno-
cytes from either female CB20 or C57BL/6 mice, respectively. Mice were sensitized, either
once or twice, in which case the second injection was given 2 wk later. Between 24 and 72
h after birth, appropriate homozygous mice were injected intraperitoneally with Tj spleno-
cytes collected from such sensitized mice 1 wk after the unique or the second sensitization.
Preparation ofAnti-allotypic Antibodies and of Allotypes and Their Detection.
￿
The details were
given elsewhere (15), except for one mAb obtained from Dr. Coutinho: RS31 (18), which is
a mouse mAb anti-Igh-6a (IgM of Igha haplotype). This mAb was used to quantify the cor-
responding allotype by RIA, as described (19). In this study, the mAb 9-8 anti-Igh-la (20)
' Abbreviations used in this paper: Tj, nylon wool-nonadherent splenocytes; Tj1s, Tj2s, Tj splenocytes
from mice sensitized either once or twice, respectively.BENAROCH ET AL.
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was linked to R-galactosidase (21) and used in an ELISA, allowing a better sensitivity than
in RIA.
In Vivo Treatments by Anti-T Cell Subset mAbs.
￿
The GK1.5 clone producing a rat anti-L3T4
(CD4) IgG2b mAb (22) and the H .35-17 .2 clone producing a rat anti-Lyt2 (CD8) IgG2b
mAb (23) were kindly supplied by Dr. Coutinho. These clones were cultured in RPMI 1640
medium supplemented with 100 IU penicillin per ml, 100 ug ofstreptomycin per ml, 2 mM
L-glutamine, 5 x 10-5 M 2-ME, 1 mM sodium pyruvate, and 10% FCS. mAb treatments
were carried out on allotypically suppressed CB20 or C57BL/6 mice.
In one experiment, we used ascitic fluid obtained from irradiated (300 rad) BALB/c host
mice for these clones. The crude ascitic fluid was partially purified by 18% Na2SO4 precipi-
tation. The immuno-fluorescence titers ofthese fractions were determined by thymocyte sus-
pension staining with FITC-labeled goat anti-rat Ig antibodies as the second step (the stained
cells were analyzed in a FACScan system; Becton Dickinson Immunocytometry Systems, Moun-
tain View, CA). The GK1.5 and the H .35-17.2 fractions had a final titer of 1 :32,000 and
1 :8,000, respectively. Mice received 300 ul of saline intravenously containing either 50 PI
of the GK1.5 fraction or 200 wl of the H.35-17.2 fraction (fourfold less of the anti-CD4 re-
agent compared with the anti-CD8 fraction, taking into account their different immunofluores-
cence titers). 4 d later, these mice received, intravenously, half of the first dose of the same
mAb fraction. They were bled 2 wk after this second injection and then every fortnight. The
eventual presence of Igh-lb in their sera was estimated by RIA.
In a second experiment, culture supernatants were used as source of mAb (the im-
munofluorescence titers were of 1 :50 and 1 :240 for the GK1 .5 and H.35-17.2 supernatants,
respectively). Mice were separated in two groups and received daily, during 7 d, 250 pl intra-
venously and 500 wl intraperitoneally injections of supernatants ofeither H.35-17 .2 or GK1 .5
clone. These mice were bled 1 d after the last injection and then weekly. Here, also, serum
Igh-lb concentrations were estimated.
Fluorescence Staining and Cytofluorographic Analysis.
￿
Before cell staining, red cells were
removed from splenocyte suspensions by treatment with Gey's solution (24). The two-step
staining procedure followed to determine the percentages of splenocytes positive for surface
Igh-5a and Igh-5b (Igh-5 is the allotypic locus for IgD) has been previously described (15).
It was also used to quantitate the percentages of CD4' and CD8` cells. For this purpose,
anti-CD4 mAb was purified from GK1.5 ascitic fluid (see above) and biotin labeled (25) while
the biotin-labeled anti-CD8 mAb (53.6.72, reference 26) was purchased from Becton Dick-
inson & Co. 106 splenocytes were incubated with either 0.5 kg of the anti-CD4 or 1 wg of
the anti-CD8 biotin-labeled mAb. We verified that under these conditions, addition of var-
ious amounts of H35-17.2 culture supernatant (containing the anti-CD8 mAb) to normal
splenocytes before incubation (or concomitantly) with biotin-labeled anti-CD8 mAb then
revealed by FITC-streptavidin, did not modify the CD8' cell percentage as compared with
the value obtained in the absence of culture supernatant. As control for cell saturation by
unlabeled mAb, incubations of normal splenocytes with the various amounts of culture su-
pernatant used then revealed by FITC-anti-rat Ig antibodies gave the same CD8' cell per-
centage value than above. The same held true for the estimation of CD4' cell percentages.
Therefore, cell-bound mAb was effectively displaced in our cell-staining conditions and thus,
eventual reduction of cell percentages will reflect disappearance of corresponding cells. Per-
centages of cells positive for surface Ig were estimated by staining with FITC-labeled Fab
fragments of goat anti-mouse Ig used at a final dilution of 1 :80. The stained cells were ana-
lyzed in a FACScan system, as fully described (15).
Southern Blot Hybridization .
￿
High molecular weight genomic DNA was prepared (27) from
liver and spleen offour different mouse strains: BALB/c (Igha); BC8 (Igha); C57BL/6 (Ighb);
and CB20 (Ighb). Each DNA sample was digested to completion by either Bgl II or Pvu II
restriction endonucleases. 10-15 gg ofeach digest were run on a 0.8% agarose gel and trans-
ferred to Genescreen membranes (New England Nuclear, Boston, MA). These were hybrid-
ized with a probe labeled with p32 by the random priming technique (28). This probe is a
380-bp Xho I-Pst I fragment essentially covering the first intron ofthe y 2a gene of BALB/c
strain, isolated from the pBG2a-4 fragment (29) . Final post-hybridization washes were per-
formed in 0.1 x SSC at 65°C, under which conditions, hybridization to alleles of y 2a gene
only is detected.894
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Results
Induction ofAllotype Suppression in CB20 Mice.
￿
The procedure followed was essen-
tially that previously established with heterozygous mice (15) . We also used the Igh
congenic partners : CB20 (Igh') and BALB/c (Igha) mice . CB20 homozygous new-
borns received either 4 x 10' Tj or 2 x 101 Tj splenocytes from BALB/c mice twice
sensitized against CB20 B splenocytes . The sera of the untreated controls and of
the treated CB20 mice were collected for >9 mo . They were studied for the expres-
sion of the Igh' allotypic forms of the IgG2a (Igh-lb), IgA (Igh-2b), and IgM (Igh-
6b) according to Herzenberg's nomenclature (30) . The neonatal treatment of 22
CB20 mice led, for all ofthem (Fig . 1), to the progressive establishment of a com-
plete suppression of Igh-lb expression . The production of the other Igh' allotypes
(Igh-2b and Igh-6b) tested in their serum was unaffected by this neonatal treatment
(not shown for Igh-2b ; and see Fig . 1 for the quantification of Igh-6b) . Moreover,
cytofluorographic studies of splenocytes collected from Igh-lb-suppressed animals
killed at two different ages revealed that the Igh-5b (IgD of Igh' haplotype) expres-
FIGURE 1 .
￿
Evolution with time
of Igh-lb, Igh-6b, and Igh-la
concentrations in the sera of
(CB20 x CB20)untreated con-
trols andrecipients ofTj spleno-
cytesfrom BALB/c mice sensi-
tized twice against CB20B sple-
nocytes . There were 12 CB20
mice injected neonatallywith 4
x 10' Tj2s (O), 10 with 2 x
107 Tj2s (A), and six were un-
treated (/) .BENAROCH ET AL.
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sion wasalso unaffected compared with splenocytesfrom untreated controls coming
from thesame offsprings (Table I). The suppression wasdemonstrated to be chronic
as it persisted for >32 wk without any break in all the treated animals and even for
>1 yr in the remaining 10 mice, which were not killed. The progressive establish-
ment ofthe suppression is slightly different between thetwo groups oftreated animals
(Fig. 1). Of those that had received 4 x 107 Tj, none were found to express Igh-lb
as of 16 wk of age, whereas, among the mice injected with half of cells, the same
result was only reached at the next bleeding, that is, 2 mo later.
Induction ofAllotype Suppression in C57BL/6 Mice.
￿
One further induction experi-
ment was attempted in homozygous C57BL/6 mice. The same pattern of chronic
allotype suppression was indeed induced in C57BL/6 homozygous mice following
a similar procedure. C57BL/6 (Igh') newborns received 4 x 107 Tj splenocytes from
BC8 (Igha) mice sensitized either once or twice against C57BL/6 B splenocytes.
Like in the experiments with CB20 mice (described in Fig. 1), Igh-lb suppression
was established at 16 wk of age in all the 13 animals belonging to the 4 x 107
Tj2s-recipient group (Table II) and did not affect the production of the other Igh'
allotypes tested in their sera (not shown for Igh-2b and Igh-6b). The percentages
of cells positive for surface Ig, Igh-5a, and Igh-5b were estimated on splenocytes
harvested at 10 wk of age from four C57BL/6 controls (51.4 ± 1.3 Ig+ ; 0.4 ± 0.1
Igh-5a+ ; and 43 .1 ± 3.2 Igh-5b+) and from four Igh-lb-suppressed C57BL/6 mice
(54.2 t 3.5 Ig+; 0.5 t 0.1 Igh-5a+ ; and 41.8 t 7.6 Igh-5b+). These data show
that the neonatal injection did not modify Igh-5b expression. Interestingly, the five
recipients of 4 x 107 Tjls continued to express Igh-lb (tested until 32 wk of age)
(Table II).
Expression ofDonor Igh° Allolypes in Hosts.
￿
Further studies in both systems (CB20
and C57BL/6) revealed, by means of a sensitive ELISA, that a weak Igh-la produc-
tion occurred in Igh-lb-suppressed mice but did not in untreated mice. With CB20
mice, it was observed that the levels of serum Igh-la concentrations seemed to be
correlated with thenumber ofinjected Tsplenocytes (Fig. 1). In addition, theIgh-1a
production seemed to decrease with time (Fig. 1). As this work was beingcompleted,
an anti-Igh-6a mAb (RS.31; reference 18) became available and allowed us, using
TABLE I
Levels of Ig, Igh-5a, and Igh-56 Expressions on Splenocytesfrom (CB20 x CB20)
Untreated Mice and Igh-1b-suppressed Mice
Untreated CB20 mice and Igh-lb-suppressed CB20 mice were killed at twodifferent ages. Half
of these allotypically suppressed mice belonged to the 4 x 107 Tj2s recipient group and the
other half belonged to the 2 x 107 Tj2s recipient group studied in Fig. 1 . Results of the FAC-
Scan analysis are expressed as mean values (and their SE) ofpercentages calculated in the in-
dicated group ofmice individually analyzed. At both ages, no significant difference wasobserved
between the splenocytes from 4 x 107 Tj2s recipients and the 2 x 107 Tj2s recipients, there-
fore, their data were grouped.
Mice n Age
wk
Percent Ig' Percent Igh-5a' Percent Igh-5b'
Untreated 4 32 57.2 t 2.3 0.4 t 0.0 41 .2 t 1 .9
Igh-lb-suppressed 4 32 57.4 t 2.5 0.8 t 0.2 46.2 t 3.1
Untreated 2 38 48.8 t 3.2 0.4 t 0.1 34.3 t 9.9
Igh-lb-suppressed 6 38 51 .0 t 2.7 0.4 t 0.3 34.0 t 5.7896
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TABLE II
Expression of Igh-1b in (C57BLI6 x C57BL/6) Untreated Controls
and Recipients of Tj Splenocytesfrom BC8 Mice Sensitized
either Once or Twice against C57BL/6 B Splenocytes
Suppression establishment within treated mice was sex independent .
Cells were injected intraperitoneally into the mice between 24 and 72 h after
their birth.
1 At 10 wk of age, four Igh-lb-suppressed mice (recipients of 4 x 107 Tj2s)
and four untreated controls were killed for cytofluorographic analysis oftheir
splenocytes.
RIA, to show that Igh-6a (IgM of Igha haplotype) production occurred in both Igh-
lb-suppressed C57BL/6 and CB20 mice at similar levels to the Igh-la production.
Nevertheless, no serum Igh-2a (IgA) production was revealed, probably because of
the low sensitivity of our immunodiffusion technique, and no significant percen-
tages of Igh-5a+ splenocytes were found in untreated and treated mice (see Table
II and above). These weak Igha productions (Igh-la and Igh-6a) were ascribed to
engraftment and differentiation ofdonor hematopoietic stem cells known to be present
in splenocyte preparations and to have the capacity of reconstituting an immune
system in irradiated hosts (31, 32).
It was previously reported (33) that BALB/c Igh' congenic mice (ICR CB17, the
mother strain ofour CB20 strain) produced not only Igh-lb but also transiently Igh-
la under certain critical conditions. Therefore, the Igh-la production observed in
our Igh-lb-suppressed CB20 mice could involve not only the differentiation ofdonor
Igha stem cells but also the expression of an endogenous Igh-1a gene under the crit-
ical condition created by the Igh-lb suppression. We wonder whether or not our
CB20 strain carries duplicated y2a genes encoding for Igh-la and Igh-lb (a situa-
tion previously observed in a wild mouse, 34). Southern blot analysis of genomic
DNA from our CB20 strain (Fig. 2) demonstrated that it possesses the b allele of
the y 2a gene but lacks the a allele. We also verified that Igh' C57BL/6 congenic
strain, BC8, carries the gene encoding for Igh-la but lacks the gene for Igh-1b.
Abrogation of the Igh-Ib Suppression by In Vivo Treatment with Anti-T Cell Subset mAb.
Among the 10 remaining Igh-lb-suppressed CB20 mice (described in Fig. 1) of 1
yr of age, four received two intravenous injections of partially purified ascitic fluid
containing a rat anti-mouse CD4 mAb (produced by the GK1.5 clone), four others
received two intravenous injections of partially purified ascitic fluid containing a
Age
Number of
Recipients (5)
of 4 x 107 Tjls`
mice showing
Recipients
of 4 x 107
production of Igh-lb
(13)
Tj2s Untreated mice (20)
wk
6 5 8 20
9 5 5 20
13 5 31 161
16 5 0 16
19 5 0 16
22 5 0 16
27 ND 0 16
32 5 ND NDBENAROCH ET AL .
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FIGURE 2 .
￿
Southern analysis of liver
genomic DNA from Igha and Ighb
mouse strains . (A) ThegenomicDNA
of indicated mouse strain origin was
digested by Pvu II . (B) The genomic
DNAofindicatedmouse strain origin
was digested by Bgl II . GenomicDNA
from spleen gave the same patterns
than genomic DNA from liver and
therefore are notshown . Numbers in-
dicate the length of fragments in kilo-
bases . Thetwo restriction endonucle-
ases used (Pvu II and Bgl II) show a
site polymorphism between the aand
b allele located in the first intron (ISV1)
of the y 2a gene. After electrophoretic
migration ofthe digests on agarose gel
and theirtransfer on Genescreen mem-
brane, this polymorphism was revealed
by means of a radiolabeled probe of
380-bp length and essentially covering
the first intron of the y 2a gene of
BALB/c (Igha) .
ratanti-mouse CD8mAb (produced by theH.35-17.2 clone), and the two remaining
CB20 mice were kept as controls . These two mAbs are of the IgG2b rat isotype,
which was demonstrated to be the most cytotoxic in vivo on mouse cells (35) . As
can be seen in Table III, one out of the four mice treated with the anti-CD8 mAb
exhibited stable production of Igh-lb as of 2 wk after the end of the treatment (>3
mo after treatment, we found 125 ug of Igh-lb per ml of serum) . Another mouse
from this group expressed up to 60 wg of Igh-lb per ml of serum 28 d after treat-
ment ; although weak, this production persisted and was of 12 gg per ml of serum
at the last bleeding, that is >3 mo after treatment . Chronic Igh-1b suppression con-
tinued to be observed in anti-CD4-treated mice .
This abrogation of suppression was repeated using chronically Igh-lb-suppressed
C57BL/6 mice of6mo of age (described in Table II) . Instead of partially purified
ascitic fluid, we used culture supernatant ofthe sameanti-CD4 and anti-CD8 mAbs
producing clones . We verified in an RIAthat both anti-CD4-andanti-C138-containing
supernatants gave no crossinhibition of the binding ofour 1125-labeled anti-Igh-lb
mAb onto Igh-lb (not shown) . The mice received the supernatants daily by both
routes (intravenously and intraperitoneally) and for 7 d. The results are summa-
rized in Table III. The anti-C134-treated mice were still Igh-lb suppressed at 1 and
21 d after treatment, however at day 35, these four mice died, probably because of
infections . In contrast, large amounts of Igh-lb were found in the serum collected
1 d after the end of the treatment from the four anti-CD8-treated mice (three of
them had -0.5 mg of Igh-lb per ml ofserum and one had 0.1 mg per ml) . However,
this production of Igh-1b then started to decrease rapidly, and 35 d after the last
injection, these four mice had almost no more Igh-lb in their serum . We decided898
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TABLE III
In Vivo Effects of Anti-CD4 or Anti-CD8 mAb on the Chroniciy of Allotypic Suppression
JO = day of the last injection (of the first treatment when there are two).
1 Mice were individually tested and the data obtained were grouped when identical .
3 These 1-yr-old mice belonged to the experiment described in Fig. 1 . They were given two intravenous
injections of either a GK1.5 (anti-CD4) or an H35-17.2 (anti-CD8) ascitic fluid partially purified.
~~ These 6-mo-old mice belonged to the experiment described in Table II. They received seven daily injec-
tions of culture supernatant of either GK-1 .5 clone (anti-CD4) or H-35-17.2 clone (anti-CD8).
These four mice had the same 7-d anti-CD8 treatment from day + 42- + 48 than before (from day - 6-0) .
" The considered mice were dead at this time.
to subject them again to exactly the same 7-d anti-CD8 mAb treatment. It led once
more to the abrogation ofIgh-lb suppression as 1 d afterthe end of the second treat-
ment, the serum of these four mice contained large amounts of Igh-lb (from 0.1-0.3
mg perml of serum). Here, again, the Igh-1b production decreased rapidly (Table III).
Experiments were carried out to estimate the lymphocyte depletion induced in
situ in different organs by the anti-T cell subset treatments. Normal C57BL/6 mice,
littermates of those described in Table III and therefore age matched, were used.
Two were kept as controls, two had the anti-CD4 mAb treatment, and two had the
anti-CD8 mAb treatment as described in Table Ill. 1 d after the last injection, the
mice were killed, and their peripheral blood lymphocytes, splenocytes, and thymo-
cytes were prepared and stained with appropriate immuno-conjugates in order to
determinethe percentages ofpositive cells for surface CD4 or CD8 molecules, respec-
tively. The stained cells were analyzed in a cytofluorograph, and the data obtained
are presented in Table IV. For these estimations of cell percentages, we used excess
amounts ofbiotin-labeled anti-CD4 or anti-CD8 mAbto displace eventual injected
mAb already bound to the corresponding cell surface antigen (see Materials and
Methods). It can be seen (Table IV) by comparison with the data acquired with
the two controls that both treatments had no effect on thymocytes but were very
effective in spleen and in blood. The anti-CD4 treatment led (without affecting
CD8+ cell percentage) to a severe depletion of the corresponding cells in periph-
eral blood and in spleen (86 and 66% depletion, respectively). The anti-CD8 treat-
Mouse type Treatment
Number
of micet
studied
Serum Igh-lb concentration on day'
-14 +14 +28 + 77 +105
wg/ml
Igh-lb-suppressed anti-CD8 1 0 0 0 0 0
CB205 1 0 133 124 241 125
1 0 6 0 0 0
1 0 42 60 23 12
anti-CD4 4 0 0 ND 0 0
none 2 0 0 ND 0 0
-7 +1 +21 +35 +41 +48 +49 +63
Igh-lb-suppressed anti-CD8 1 0 567 55 9 189 31
C57BL/611 1 0 471 29 0 New 116 7
1 0 546 63 12 treatment) 285 69
1 0 119 6 0 156 21
anti-CD4 2 0 0 0 -*'
2 0 0 - _V+
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U
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ment did not modify CD4+ cell percentage but resulted in 98% depletion of CD8+
cells in peripheral blood, and this depletion reached 96% in spleen.
Discussion
In the current study, we have demonstrated the possibility of obtaining chronic
suppression of Igh-lb expression (IgG2a of Ighb haplotype) in homozygous Ighb'
mice. Forthis purpose, we followed the procedurewe have previously used to induce
Igh-lb suppression in heterozygous Ighb mice (15). It consisted here of injecting
homozygous Ighb' newborn mice (CB20 or C57BL/6) with T splenocytes from
Ighala congenic adult donors (BALB/c or BC8 mice, respectively) twice sensitized
against congenic Ighb B splenocytes. The totality of the treated homozygous mice
developed, from 16-24 wk of age, a chronic Igh-lb suppression. This suppression
can be compared with that induced in heterozygous Ighb/a mice having maternally
inherited the Ighb haplotype (15), because in both situations, the newborns have at
the time of treatment Ighb allotypes of maternal origin transmitted through the
placenta. In both cases, the time necessary for the establishment of suppression is
nearly the same, and the pattern of suppression induced by injection of T cells from
twice sensitized mice (Tj2s) is very similar in that a chronic suppression of Igh-lb
expression was obtained without affectingthe otherproductionstested ofIgM, IgD,
and IgA of Ighb haplotype. In contrast to the homozygous recipients of 4 x 101
Tj2s, which all developed a chronic Igh-lb suppression, all the homozygous mice
having received the same number of Tj1s were still expressing Igh-lb at 30 wk of
age. These data show that the second sensitization significantly enhanced the sup-
pression inducer activity within the Igha donor's T splenocytes. In the same manner,
we hadpreviously shownwith heterozygotes that this activity was strongly increased
in Tj from Igha mice sensitized once compared with normal Igha mice (15).
While we were establishing our data, a report on allotypic suppression induced
by total spleen cells neonatally injected in heterozygous mice was published (36)
in which the authors state that "neonatal IgG2ab suppression was harder to achieve
in homozygous CB20 mice, andtiters scattered. However, at the age of 1.5 yr, seven
out of eight animals did not have detectable allotype b levels anymore. Allotype a
titers were high instead (data not shown)."
An important face of the current report is to present the first example of in situ
experimental breaking of mouse chronic allotypic suppression. In vivo treatments
ofIgh-lb-suppressedmice were performedwith anti-CD4 or anti-CD8 mAb. In both
systems (CB20 andC57BL/6), abrogation ofthe suppressionwas observed with anti-
CD8 treatmentonly. In afirst series of experiments, we used mAbs partially purified
from ascitic fluids. Three out of the four mice that had received two intravenous
injections of anti-CD8 preparation were shown to express serum Igh-lb 2 wk after
the last injection. Two of these three mice permanently expressed this allotype
(meaning, during >3 mo, date of the last bleeding tested), while the Igh-lb produc-
tion of the other mouse was only transient. We have to emphasize that during all
our studies we never observed any spontaneous break of Igh-lb suppression.
In a second series of experiments, 1-wk in vivo treatment with culture superna-
tant containing the anti-CD8 mAb was sufficient to abrogate the chronic suppres-
sion as judged by the detection of large amounts of Igh-lb (up to 0.5 mg/ml) in the
serum of the treated mice 1 d after the end of the treatment. At this time, CD8+BENAROCH ET AL.
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cell percentages were severely reduced in spleen and in blood (96 and 98o7o ofdeple-
tion, respectively), while CD4+ cell percentages remained similar to those found
with untreated controls. Concerning the specificity ofthe anti-CD4 mAb, the con-
verse situation was observed in 1-wk-treated mice. We verified that the observed
decreases of cell percentages were not due to shielding of CD4 and CD8 antigenic
determinants by the injected mAbs, butreflectedeffectivecell depletion. This deple-
tion of CD8+ cells in homozygous allotypically suppressed mice was sufficient to
quickly reversethe equilibrium between thehelper and suppressive effects upon the
Igh-lb producers.
This induced Igh-lb production shows that the maintenance of the suppression
was not the result of a clonal deletion but an active CD8+ lymphocyte (suppressor
or cytotoxic cell)-dependent mechanism that is reversible. In contrast, experiments
carried out with heterozygous mice (manuscript in preparation) show that the ca-
pacity of sensitized T cells to induce Igh-lb suppression is abolished by both either
anti-CD4 or anti-CD8 treatments. In addition, the Igh-1b production induced by
anti-CD8 treatment seems too rapid and too large to be ascribed to B lymphocytes
derived from remote stem cells after the mAb treatment. It could be proposed that
Igh-lb producer lymphocytes were, before the in vivo mAb treatment and, thus,
during the life of the Igh-lb-suppressed mice, very close to producing this allotype
(anassumption undercurrent investigation). This impliesthat these Igh-lb producer
cells permanently trigger the involved CD8+ cells, which agrees with our previous
observation that T splenocytes from sensitized Ighla mice and from Igh-lb-sup-
pressed Igh"" mice had the same efficiency in inducing suppression in heterozygous
Fl mice (15), whereas, normal T cells from Ighala mice had a much lower one (14).
Nevertheless, aftertheappearance oflarge amounts of serum Igh-lb in these anti-
C138-treated mice, the quantities started to decrease, and 35 d after the last injec-
tion, all four mice had almost no Igh-lb in their serum. The difference observed
between the two experiments in the duration of Igh-lb expression after the anti-
CD8 treatment might be dueto the fact that mice from the first experimental series
were 6 mo older than mice from the second one and/or might reflect the difference
in mAb concentration in ascitic fluids compared with culture supernatants, which
were used forthetreatments. This concentrationwasindirectly estimated by thymocyte
staining giving in the first case an immunofluorescence titerof 1:8,000 and of 1:240
in the second case.
In animals having suffered the anti-CD8 culture supernatant treatment, this Igh-
lb suppression was then abrogated once more by a similar 1-wk anti-CD8 treat-
ment. From these data, we propose that after theclearanceof the injected anti-CD8
mAbcontaining culture supernatant, newT cellsare raised with an activity directed
against the reappearing Igh-lb producers, establishing again the observed suppres-
sion. Further, these T cells could derive from precursors (whatever their origin: Igha
donors or Ighb hosts) coming from the thymus (an organ unaffected by the mAb
treatment) which have matured in CD8+ cells.
Summary
We report here the successful induction of allotype suppression in homozygous
Ighb/b mice (CB20 or C57BL/6) by neonatal injection of T splenocytes from Igh'
congenic sensitized mice (BALB/c or BC8, respectively). The sensitization of the902
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T cell donors was achieved by two intravenous injections of B splenocytes from Ighb
congenic mice. Treated homozygous Ighbl mice developed, as of 16-24 wk of age,
a chronic suppression of Igh-1b expression (IgG2a of Ighb haplotype). The other
productions tested (IgM, IgD, and IgA) of Ighb haplotype were unaffected.
In vivo treatment with cytotoxic anti-CD4 or anti-CD8 mAb of mice subjected
to chronic Igh-1b suppression clearly showed that CD8+ lymphocytes (suppressor
or cytotoxic cell) were essential for the maintenance of the suppression. The sup-
pression was indeed abrogated after a 1-wk treatment with anti-CD8 mAb containing
culture supernatant, whereas, the anti-CD4-treated mice continued to be subjected
to suppression. This anti-CD8 in vivo treatment was shown to have no effect on
thymus but to severely reduce the percentages of CD8+ cells in spleen and in pe-
ripheral blood without affecting the percentages of CD4` cells, leading to a large
and rapid Igh-lb expression (up to 0.5 mg per ml of serum, the day after the end
of the treatment). This suppression abrogation, and thus the Igh-1b expression, was
either transient or permanent. When it was transient, a second 1-wk treatment with
anti-CD8 mAb containing culture supernatant induced once again a rapid and
significant production of Igh-lb (up to 0.3 mg of Igh-lb per ml of serum).
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